Eisai Co.,Ltd. Q2 FY2027 earnings call

• Strong Financial Execution: Operating profit rose 20.4% to 41.4 billion yen, while core operating profit increased 28.6% to 43.1 billion yen. Progress toward the full-year forecast is on track, with revenue at 53.2% and operating profit at 59.2% of annual targets.
• Lekembe (Alzheimer’s Treatment) Momentum: The launch of the subcutaneous formulation (iClick) has accelerated uptake significantly. In the U.S., patient initiation rates are four times faster than previous IV-only trends, and prescriber adoption is six times faster. iClick now accounts for nearly 10% of net sales.
• Operational Efficiency & Convenience: The shift from IV infusions to home-based auto-injectors reduces burdens on healthcare providers (no need for infusion chairs/beds) and patients (travel/time savings). This flexibility lowers the barrier to treatment initiation, allowing physicians previously hesitant due to logistical constraints to prescribe the drug.
• Pipeline Advancements: Development continues on anti-tau antibody etalanetag and orexin-2 receptor agonist ledasorexon (for narcolepsy). Ledasorexon achieved its Phase II primary endpoint (LPI). Etalanetag trials in the Dominantly Inherited Alzheimer Network (DIAN) cohort are providing critical data for potential preclinical AD indications.

The pharmaceutical business, driven by the '3L' products (Lenvima, Devigo, and Lekembe), was the primary revenue driver. Total revenue reached 470 billion yen, a 17.5% year-on-year increase. Specifically, Lenvima generated approximately 200 billion yen in the first half of the fiscal year, representing steady growth. Devigo achieved significant expansion with revenue nearing 40 billion yen, reflecting a 36% year-on-year increase. Lekembe performed exceptionally well with revenue of 61.5 billion yen, up 50% year-on-year, outpacing initial plans. The pharmaceutical segment accounted for 462.1 billion yen of the total 470 billion yen revenue, contributing roughly 98.3% to the firm's top line.

• Full-Year Forecast Maintained: Management confirmed it will not change the full-year fiscal 2026 earnings forecast despite strong H1 performance, citing unpredictable uncertainties.
• Operating Profit Target: The company reaffirmed its target of achieving 70 billion yen in operating profit for the full year.
• Three-Year Outlook: Core operating profit is targeted at 90 billion yen by FY2028. An intermediate target for FY2027 was not explicitly disclosed but is implied to be between 70 billion and 90 billion yen.
• Revenue Growth Expectations: Continued double-digit growth is expected in the second half, driven by Lekembe’s iClick launch and global expansion of Lenvima.

• Regulatory and Reimbursement Uncertainty: While Medicare Part D inclusion is expected in January 2027, final coverage terms and out-of-pocket cost structures remain under negotiation. Delays or unfavorable terms could impact patient access.
• Geopolitical and Political Factors: U.S. midterm election results may lead to increased congressional scrutiny on pharmaceutical pricing and affordability, potentially affecting market dynamics.
• China Market Access: The postponement of Lekembe’s inclusion in China’s National Reimbursement Drug List (NRDL) limits immediate mass-market access, though commercial insurance listing provides some mitigation.
• Competitive Landscape: Intense competition in the anti-amyloid therapy space requires continuous differentiation through convenience and efficacy data to maintain market share.

Q: Analyst from JP Morgan asked about the sustainability of iClick uptake in the US and factors driving the rapid adoption compared to IV infusion.

A: Management explained that the fundamental clinical value of Lecambi combined with the convenience of SC administration has lowered treatment hurdles. Patients benefit from avoiding clinic visits and infusion chair reservations, while physicians appreciate the reduced operational burden. This flexibility allows both existing and new prescribers to adopt the therapy more easily, sustaining momentum beyond just the initial launch phase.

Q: Analyst from Daiwa Securities questioned why Cost of Sales increased in Q2 despite being within plan, asking if product mix changes were the cause.

A: CFO Oyama confirmed that a change in product mix contributed to the increase, specifically noting that Lenvima revenue was flat while Lekembe grew. Additionally, production losses in Q1 were smaller than expected, leading to a slight increase in cost ratios in subsequent periods, but overall costs remain controlled within planned ranges.

Q: Analyst from UBS Securities asked about the comparability of Medicare Part D coverage figures cited by management versus Biogen’s announcements, and whether Step Therapy requirements exist.

A: Management clarified that their data is directly shared with Biogen, making it apple-to-apple comparable. Approximately 67% of the subscriber base is expected to be covered starting January 2027. Importantly, no Step Therapy is required, allowing patients to use the drug from initiation without prior authorization hurdles, which supports easier access.

Q: Analyst from Macquarie Securities asked about the specific split between IV and iClick usage among new patients and the rationale behind selecting gantenerumab-treated patients for the DIAN-TU study.

A: Management declined to provide granular real-time splits between IV and iClick usage due to timing granularity issues. Regarding the study design, Chief Clinical Officer Lynn Kramer explained that all original DIAN-TU participants were eventually converted to gantenerumab and later lecanemab; thus, the current cohort reflects long-term exposure to these therapies rather than an active control arm comparison.

Q: Media representative from Nikkei asked about the potential impact of recent U.S. midterm elections on the business environment and drug affordability policies.

A: Management noted that while immediate impacts are not visible, the Democratic majority in Congress may lead to stronger scrutiny of pharmaceutical pricing and affordability initiatives. The company will closely monitor developments related to Medicare Final Negotiation (MFN), tariffs, and China-related bills, adjusting strategies as the political landscape evolves.